All In Biotech

Drug Trial Radar · NCT07186842

A Clinical Trial to Test if the Investigational Drug BNT329 is Safe and Potentially Beneficial for People With Advanced Solid Tumors Known to Express the Tumor Marker CA19-9

First-in-human, Open-label, Multi-site, Phase I/IIa, Dose Escalation Trial With Expansion Cohorts to Evaluate Safety and Preliminary Efficacy of BNT329 in Participants With Advanced Solid Tumors Known to Express CA19-9

Last checked: Nov 19, 2026Latest source record: Oct 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 245 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

245

Planned (sponsor's estimate)

Start

Nov 18, 2025

Primary completion

May 2030

Study completion May 2030

Sponsor

Lead sponsor
BioNTech SEIndustry
Sponsor type
Industry
First posted
Sep 22, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The main goal of this study is to evaluate the safety of BNT329 and to identify the best dose of BNT329. This will be done by measuring the number of side effects that participants experience and how severe they are. The second goal of this study is to evaluate how well BNT329 works. This will be done by measuring the number of participants who respond to the treatment. The length of time where the tumor does not grow or spread will also be measured. The study will also evaluate how BNT329 moves into, through, and out of the body and how the treatment affects the body.

Conditions

  • Advanced Solid Cancers

Interventions

  • BNT329Drug

    Intravenous (IV) infusion

  • CA19-9-targeting monoclonal antibodyDrug

    Monoclonal antibody

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Parts A and B - Occurrence of dose-limiting toxicities within a participantTime frame: First 21 days (Part A) or 28 days (Part B) after the first dose of BNT329.
  2. Parts A, B, and D - Occurrence of treatment-emergent adverse events (TEAEs), Grade ≥3 TEAEs, serious adverse events (SAEs), treatment-related TEAEs, treatment-related Grade ≥3 TEAEs, and treatment-related SAEsTime frame: From first dose of BNT329 until 60 days after the last dose of BNT329 (up to 26 months).
  3. Parts A, B, and D - Occurrence of dose interruptions, reductions, and discontinuation of BNT329 due to TEAEsTime frame: From the time of initiation of the first dose of BNT329 until 60 days after the last dose of BNT329 (up to 26 months).
  4. Part D - Objective response rate (ORR)Time frame: From first dose of BNT329 until end of study (up to approximately 36 months).

Locations

18 sites in 5 countries. Site status is shown where the registry gives one.

  • SCRI at HCA Health One

    Denver, Colorado · Recruiting

  • Florida Cancer Specialists

    Orlando, Florida · Recruiting

  • Karmanos Cancer Institute

    Detroit, Michigan · Recruiting

  • Memorial Sloan Kettering Cancer Center

    New York, New York · Recruiting

  • Monash Health

    Clayton, Australia · Recruiting

  • Austin Health

    Heidelberg, Australia · Recruiting

  • St. Josef-Hospital im Katholischen Klinikum Bochum

    Bochum, Germany · Recruiting

  • Klinikum der Universität München

    München, Germany · Recruiting

  • Universitaetsklinikum Ulm

    Ulm, Germany · Recruiting

  • Hospital Universitari Vall d'Hebron

    Barcelona, Spain · Recruiting

  • Hospital San Pedro

    Logroño, Spain · Recruiting

  • Hospital Universitario HM Sanchinarro - START Madrid CIOCC

    Madrid, Spain · Recruiting

  • Hospital Universitario Quironsalud Madrid - NEXT Oncology

    Pozuelo de Alarcón, Spain · Recruiting

  • St James´s University Hospital

    Leeds, United Kingdom · Recruiting

  • Royal Free Hospital

    London, United Kingdom · Recruiting

  • The Christie NHS Foundation Trust

    Manchester, United Kingdom · Recruiting

  • Northern Centre for Cancer Research

    Newcastle upon Tyne, United Kingdom · Recruiting

  • The Royal Marsden Hospital

    Sutton, United Kingdom · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.